Indoco Remedies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Indoco Remedies wird ein jährliches Gewinn- und Umsatzwachstum von 114.1% bzw. 13.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 112.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.2% betragen.

Wichtige Informationen

114.1%

Wachstumsrate der Gewinne

112.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	15.9%
Wachstumsrate der Einnahmen	13.3%
Zukünftige Eigenkapitalrendite	11.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Apr 2025

Jüngste Aktualisierungen zum künftigen Wachstum

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Jan 24

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Recent updates

Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive

Jan 29

Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion

Jan 26 Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Jan 24

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Gewinn- und Umsatzwachstumsprognosen

NSEI:INDOCO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	22,512	1,442	1,027	N/A	4
3/31/2026	19,721	775	206	N/A	5
3/31/2025	16,601	-453	-982	N/A	4
12/31/2024	17,243	-107	N/A	N/A	N/A
9/30/2024	17,732	321	-3,076	2,220	N/A
6/30/2024	18,223	767	N/A	N/A	N/A
3/31/2024	18,173	985	-2,706	1,567	N/A
12/31/2023	17,958	1,016	N/A	N/A	N/A
9/30/2023	17,356	1,134	-911	1,442	N/A
6/30/2023	16,869	1,281	N/A	N/A	N/A
3/31/2023	16,686	1,423	-284	1,788	N/A
12/31/2022	16,496	1,569	N/A	N/A	N/A
9/30/2022	16,084	1,617	85	1,703	N/A
6/30/2022	15,622	1,537	N/A	N/A	N/A
3/31/2022	15,408	1,548	485	1,738	N/A
12/31/2021	14,368	1,393	N/A	N/A	N/A
9/30/2021	14,110	1,317	257	1,391	N/A
6/30/2021	13,524	1,157	N/A	N/A	N/A
3/31/2021	12,415	930	54	822	N/A
12/31/2020	12,084	734	N/A	N/A	N/A
9/30/2020	11,654	571	387	931	N/A
6/30/2020	11,298	393	N/A	N/A	N/A
3/31/2020	11,066	241	644	1,228	N/A
12/31/2019	10,909	302	N/A	N/A	N/A
9/30/2019	10,640	264	N/A	N/A	N/A
6/30/2019	10,071	111	N/A	N/A	N/A
3/31/2019	9,684	-29	352	1,321	N/A
3/31/2018	10,424	412	N/A	1,227	N/A
3/31/2017	10,968	771	N/A	886	N/A
3/31/2016	10,081	819	N/A	1,122	N/A
3/31/2015	8,570	828	N/A	1,090	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INDOCO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (6.7%).

Ertrag vs. Markt: INDOCO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: INDOCO wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: INDOCODie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.8% pro Jahr).

Hohe Wachstumseinnahmen: INDOCODie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: INDOCODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.2%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/04/30 03:01
Aktienkurs zum Tagesende	2025/04/30 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Indoco Remedies Limited wird von 17 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
Sarabjit Nangra	Angel Broking Private Limited
Srivathsan Ramachandran	Avendus Spark

Indoco Remedies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 16%

Recent updates

New minor risk - Share price stability

Joint MD & Executive Director recently bought ₹1.0m worth of stock

Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive

Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Indoco Remedies Limited to Report Q3, 2025 Results on Jan 21, 2025

MD & Executive Director recently bought ₹4.6m worth of stock

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022